67 results about "Ovarian reserve" patented technology

The invention relates to the technical field of biomarkers, in particular to a blood biomarker combination for prediction and auxiliary diagnosis of ovarian reserve hypofunction (DOR), a corresponding detection kit and application of the blood biomarker combination. According to the invention, the content change of the nicotinamide mononucleotide (NMN) and the metabolite combination thereof in serum or plasma is screened for the first time and can be used as a detection index for predicting the ovarian reserve function decline. Based on the biomarker combination, the invention further provides an in-vitro detection kit containing a related standard substance, an internal standard solution and an extracting solution, and a data analysis method combined with a random forest model, so that an individual with a normal ovarian reserve function and an individual with hypofunction can be accurately distinguished. The method is noninvasive, simple, convenient, high in sensitivity and suitable for early recognition and layered screening of clinical ovarian reserve hypofunction.

The invention relates to an ovarian reserve hypofunction prediction method based on multi-data fusion, and the technical scheme comprises the following steps: regularly collecting biomarker data related to ovarian reserve, including anti-mullerian canal hormone AMH, follicle stimulating hormone FSH, luteinizing hormone LH, estradiol E2, and ultrasonic image data including follicle quantity and ovarian volume; acquiring dynamic change curve data and capturing the change trend of the ovarian reserve function when the acquisition time point covers the key stage of the menstrual cycle; analyzing the biomarker data acquired for multiple times by using an LSTM deep learning model, and modeling a change trend of the ovarian reserve function of each patient along with time; by analyzing the periodic fluctuation of AMH and FSH biomarkers, the decline time node of the ovarian reserve function in the future is predicted; and on the basis of the LSTM deep learning model of S1.1, performing personalized risk assessment in combination with individual characteristics of patients including age, genes, lifestyles and disease histories.

The invention discloses a traditional Chinese medicine composition, a preparation method thereof and an application of the traditional Chinese medicine composition in preparation of a medicine for preventing and treating ovarian reserve hypofunction, and belongs to the technical field of traditional Chinese medicines. The composition is prepared from the following raw materials in parts by weight: 10 to 15 parts of radix paeoniae alba, 6 to 10 parts of radix bupleuri, 10 to 15 parts of radix rehmanniae preparata, 15 to 30 parts of stir-fried rhizoma dioscoreae, 12 to 20 parts of semen cuscutae, 10 to 12 parts of radix angelicae sinensis, 10 to 15 parts of poria cocos, 12 to 25 parts of fructus ligustri lucidi, 10 to 15 parts of radix salviae miltiorrhizae, 10 to 15 parts of fructus corni and 10 to 15 parts of radix morindae officinalis. The traditional Chinese medicine composition can obviously reduce the level of follicle-stimulating hormone (FSH) of cis-platinum model mice, increase estradiol (E2), increase the number of follicles at all levels, especially the number of primordial follicles, and reduce the number of atresia follicles; the ovarian function of naturally aged mice can be improved, FSH (follicle stimulating hormone) is reduced, anti-mullerian hormone (AMH) and E2 are increased, and the quantity of follicles at all levels, especially the quantity of corpus luteum, primordial follicles and anterior sinus follicles, is increased; therefore, the composition disclosed by the invention has an obvious protection effect on the hypoovarian reserve function.

The invention provides a strain of lactobacillus plantarum YS-AG23 with high antioxidant activity, and a rhizoma polygonati and radix angelicae sinensis fermented product obtained by fermenting rhizoma polygonati and radix angelicae sinensis with the strain of lactobacillus plantarum YS-AG23. In a D-galactose induced premature ovarian failure mouse model, the fermentation product can regulate up the levels of antioxidant and stress protection genes SOD2 and HO-1 and an anti-aging gene SIRT1 by regulating down the expression of a key gene AGER of an inflammation and oxidative stress pathway, so that the oxidative stress and inflammatory response of model mouse ovarian tissues are remarkably reduced; meanwhile, the serum hormone level can be specifically adjusted, the serum estradiol (E2) level can be increased, the follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels can be reduced to be close to the normal range, the expression of anti-mullerian hormone (AMH) and hormone regulatory gene LHR of ovarian reserve markers can be up-regulated, the proliferative activity and estrogen secretion function of follicular granulosa cells can be improved, and the effect of preventing ovarian reserve is achieved. The wet weight of atrophic uterus and ovary of the model mouse is remarkably increased, uterine and ovary atrophy is effectively reversed, and the ovarian reserve function of the D-galactose induced premature ovarian failure model mouse is recovered. Besides, in an H2O2-induced human dermal fibroblast aging model, the yeast can improve the activity of aging cells in a concentration-dependent manner and reduce the level of reactive oxygen species (ROS) in the cells; in addition, by up-regulating the expression of a collagen synthesis key gene COL1A1 and down-regulating the expression of a cell senescence marker gene p16, skin cell senescence caused by oxidative stress can be effectively improved. In conclusion, the polygonatum sibiricum and angelica sinensis leavening can synchronously improve premature ovarian failure and skin cell senescence caused by oxidative stress by accurately regulating and controlling oxidative stress, inflammatory response and tissue function related genes, and has wide application potential.

The invention provides a traditional Chinese medicine composition for treating ovarian reserve function decline. The traditional Chinese medicine composition is prepared from the following medicines in parts by mass: 9-30 parts of radix astragali preparata, 6-20 parts of roasted rhizoma atractylodis macrocephalae, 10-15 parts of poria cocos, 2-10 parts of radix glycyrrhizae preparata, 6-20 parts of semen cuscutae, 9-20 parts of radix dipsaci (dipsacus root), 6-12 parts of herba lycopi and 6-15 parts of lily. Experimental results show that the traditional Chinese medicine composition is suitable for improving the ovarian function of a patient suffering from spleen-kidney deficiency type ovarian reserve function decline.

The invention relates to the technical field of traditional Chinese medicine conditioning, in particular to eight-treasure brewing paste for treating ovarian reserve hypofunction and a preparation method of the eight-treasure brewing paste. The eight-treasure brewing paste is prepared from the following raw materials: prepared rehmannia root, white paeony root, Chinese angelica, ligusticum wallichii, radix pseudostellariae, poria cocos, bighead atractylodes rhizome, liquorice, astragalus membranaceus, parasitic loranthus, bran-fried Chinese yam, salted fructus alpiniae oxyphyllae, cortex albiziae, vinegar-processed rhizoma cyperi, fructus akebiae, donkey-hide gelatin, tortoise-shell glue, fingered citron, wine-processed rhizoma polygonati, caulis spatholobi, mulberry and pericarpium citri reticulatae through pretreatment, water decoction extraction, vacuum concentration, glue melting and mixing and paste collection. The prepared eight-treasure brewing paste has the effects of benefiting qi, nourishing blood, tonifying kidney, soothing liver and regulating Chong and Ren meridians, can improve related symptoms of ovarian reserve hypofunction and regulate the balance of qi, blood, yin and yang of a body, and is scientific in preparation process, sufficient in effective component dissolution, convenient to take and absorb in dosage form and suitable for large-scale popularization and application. And a safe and convenient new choice is provided for the traditional Chinese medicine conditioning of the ovarian reserve hypofunction.

The invention relates to application of icariin in preparation of a medicine for treating ovarian reserve function decline diseases. The ovarian reserve function decline disease is infertility caused by ovarian reserve function decline. It is found through experiments that icariin improves the number of DOR mouse sinus follicles; the effect of icariin on the hormone level of a DOR mouse; the influence of icariin on DOR mouse ovarian apoptosis; the influence of icariin on the ovary mitochondrial function of the DOR mouse; icariin (ICA) can be used for increasing the proliferation of ovarian granular cells induced by CTX; icariin can improve the mitochondrial function; the icariin can improve the mitochondrial membrane potential and reduce the generation of active oxygen. The traditional Chinese medicine monomer icariin has a considerable clinical application prospect in improvement of mouse ovarian reserve function decline.

The invention belongs to the field of animal model construction, and particularly relates to application of an NFATC2IP gene knockout mouse model. Experiments prove that after the NFATC2IP gene is knocked out, the mouse has the characteristic changes of ovarian weight reduction, volume reduction, estrus cycle disorder, fertility reduction, AMH reduction, FSH increase and the like. It is indicated that the NFATC2IP gene is a key factor for maintaining ovarian reserve and endocrine balance, and an NFATC2IP gene knockout mouse can be used for revealing the occurrence mechanism of ovarian dysfunction and can also be used for screening of novel ovarian protection drugs, research of a hormone regulation mechanism and discovery and verification of biomarkers.

The invention belongs to the technical field of in-vitro immunodiagnosis, and particularly relates to a test strip for combined detection of AMH and FSH and a preparation method thereof.The test strip comprises a pretreated combination pad, a pretreated sample pad and a nitrocellulose membrane, and the nitrocellulose membrane is coated with an antibody; the preparation method of the test strip comprises the following steps: pretreating the conjugate pad with a conjugate pad pretreatment solution, drying, and spraying a fluorescent microsphere labeled antibody mixed solution; pretreating a sample pad with a sample pad pretreatment solution, and drying for later use; diluting the antibody by adopting a coating antibody diluent, marking on a nitrocellulose membrane, and drying for later use after marking is finished; the sample pad, the combination pad, the nitrocellulose membrane and the water absorption pad are sequentially pasted to a PVC bottom plate, and the test strip is cut. The test strip can jointly detect AMH and FSH indexes, is easy to operate, small in harm to the human body, economical and applicable, comprehensively detects multiple ovarian reserve function biological indexes, can more comprehensively and accurately evaluate the female fertility, and has good application prospects. The actual clinical requirements are met.

The application relates to an ovarian reserve function index processing data evaluation method and system, which comprises the following steps: obtaining a clinical detection data set containing the age of a female and the measured value of serum anti-Mullerian hormone, screening, and obtaining an effective sample set; grouping the effective sample set and calculating the mean, standard deviation and sample number thereof to obtain an original statistical distribution benchmark; positioning a core dense area of the original statistical distribution benchmark to obtain a core dense data intercept segment; converting the core dense data intercept segment into a standardized core data set, constructing an age-AMH linear regression model based on the standardized core data set; calculating the same-age theoretical AMH value through the linear regression model to obtain a JCA index; and performing multi-level risk quantitative evaluation on the JCA index to obtain a quantitative evaluation result. The embodiment solves the technical problems of age incomparability, poor distinguishability and lack of unified quantitative standard in the prior art.

The invention discloses application of spermidine in preparation of a preparation for improving fertility of female mammals, and belongs to the technical field of reproductive biology. According to the invention, spermidine with different concentrations is introduced into mice, and the effect of spermidine on ovarian hormone secretion, ovarian reserve level and follicle number of female mammals is determined in a diet intake manner, so that the fertility of female animals is improved; it is found that spermidine can effectively improve the ovarian function, increase the secretion level of E2, P4, LH and AMH hormones closely related to the ovarian function, reduce the number of atresia follicles of the ovarian and increase the litter birth number of female mice by 1-2, and the spermidine has good animal breeding and livestock raising application prospects.

The invention discloses a synergistic anti-oxidation urolithin A composition and application thereof in improving the ovarian function direction, and relates to the technical field of biological medicine, and the active ingredients of the composition comprise 10-100 parts of urolithin A and 6-40 parts of coenzyme Q10. According to the composition disclosed by the invention, the used raw materials are food-grade raw materials such as urolithin A and coenzyme Q10, and the urolithin A and the coenzyme Q10 are matched within a certain range, so that a good synergistic interaction effect can be achieved, and the composition has a good antioxidant effect; meanwhile, the composition also has the effects of effectively improving the ovarian reserve function, regulating the hormone level, improving menstruation, skin, emotion, sleep and the like at a low dosage level, and is effective and safe.

The application relates to the technical field of animal model construction, in particular to a construction method and application of a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model. The construction method comprises the following steps: a model group animal is subjected to modeling by adopting the method of senna leaf water decoction gavage and hydrocortisone and cyclophosphamide injection, and a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model is obtained. In the application, the three of senna leaf, hydrocortisone and cyclophosphamide are used in synergy to administer the animal model, and the complex syndrome of the clinical spleen-kidney yang deficiency type DOR is accurately reproduced, and modern scientific basis is provided for the theories of traditional Chinese medicine such as the same treatment for different diseases.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for improving ovarian function damage and degeneration and a preparation method thereof. The invention discloses the GnRH agonist effect of dihydromyricetin DMY for the first time, and the affinity of dihydromyricetin DMY to a GnRH receptor and the GnRH agonist effect of dihydromyricetin DMY are verified through in-vitro experiments. Model animal experiments further prove that the dihydromyricetin DMY has a protective effect on ovarian function impairment caused by chemotherapy. Experiments prove that the dihydromyricetin DMY is given while the cyclophosphamide (CTX) is used for chemotherapy, so that the damage of the dihydromyricetin DMY to the ovarian function during chemotherapy can be reduced, and a protection effect is also achieved on the recovery of the ovarian function after drug withdrawal. The protection effect is reflected on the endocrine function and the reserve function of the ovary, and the preserved ovary reserve function can achieve the pregnancy result after chemotherapy is finished, which indicates that the dihydromyricetin DMY also plays the protection effect on the fertility function of the ovary.

One aspect of the invention provides a method of ovarian protection by administering to a female subject a composition comprising Mullerian inhibiting substance (MIS). Ovarian protection can be an induced arrest of folliculogenesis to preserve fertility. In some embodiments, ovarian protection is oncoprotection, the protection of the ovarian function during a cytotoxic treatment, e.g., chemotherapy. Another aspect of the invention relates to a method of treating PCOS, the method comprising administering to a female subject a composition comprising recombinant MIS protein.

The application belongs to the technical field of biology and particularly relates to application of phosphatidylglycerol. The phosphatidylglycerol PG (20:4_22:6) is used as a biomarker, and through analysis on metabolites of follicular fluid, the application realizes diagnosis of decreased ovarian reserve (DOR) with high sensitivity, high specificity and high accuracy.

This invention discloses a liposome targeting ovarian mitochondria with mitochondrial optimization function, comprising a liposome body, PQQ, ovarian-specific targeting peptides YAGKLLISLSEERISAHHVP and TPP. PQQ is encapsulated within the liposome body, and the ovarian-specific targeting peptides YAGKLLISLSEERISAHHVP and TPP are respectively modified on the surface of the liposome body via amphiphilic polymer anchoring sites. This invention also discloses its preparation method and its application in the preparation of drugs for treating ovarian reserve insufficiency. The liposome of this invention significantly improves drug bioavailability, successfully overcomes the bottlenecks of existing delivery technologies, achieves highly efficient optimization of ovarian mitochondrial function, and provides a breakthrough solution for the precision treatment of diseases such as ovarian reserve insufficiency.

The invention discloses a traditional Chinese medicine composition for treating ovarian reserve function decline. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 10-20 parts of radix rehmanniae preparata, 10-20 parts of radix rehmanniae, 8-15 parts of radix glehniae, 10-20 parts of radix ophiopogonis, 5-10 parts of colla corii asini, 8-15 parts of rhizoma dioscoreae, 8-15 parts of herba dendrobii, 8-15 parts of tortoise plastron, 8-15 parts of semen euryales, 8-15 parts of semen cuscutae and 8-15 parts of radix morindae officinalis. The traditional Chinese medicine composition can improve follicle development disorder and sex hormone disorder of rats with ovarian reserve function insufficiency induced by cyclophosphamide, the number of atresia follicles and corpus luteum is obviously reduced, and the traditional Chinese medicine composition has a good treatment prospect.

The invention discloses an exogenous FSH decreasing injection optimization method for inducing donor cattle superovulation, and relates to the technical field of animal husbandry biological breeding. The method comprises the following steps: acquiring physiological feature data and ovarian reserve function data of donor cattle, constructing an ovarian sensitivity evaluation model and calculating an ovarian sensitivity index; mapping the ovarian sensitivity index into an elimination rate constant, and generating an accumulated blood concentration sequence and a blood concentration metabolism curve according to a superposition principle by combining an injection time point sequence, an injection dosage sequence and a pharmacokinetic parameter table; a multi-target particle swarm optimization algorithm is adopted, follicular development synchronization rate maximization and ovarian over-stimulation risk minimization serve as targets, the fitness is calculated based on a blood concentration metabolism curve, iterative optimization is conducted, and the optimal initial injection dosage and the optimal decline gradient coefficient are output; generating an optimal decline dosing scheme parameter set according to the optimal decline dosing scheme parameter set; while the follicle development consistency and superovulation output are improved, the superovulation treatment stability is improved.

The invention is in the field of medical formulations. Specifically, the invention provides a pharmaceutical composition, the pharmaceutical composition comprises in-vitro regenerated platelets and / or a culture supernatant of the in-vitro regenerated platelets, and the in-vitro regenerated platelets have the following characteristics: the FGF level is significantly increased and / or the VEGF level is significantly increased; the pharmaceutical composition is used for promoting ovarian regeneration, improving ovarian endocrine function, improving ovarian reserve function, and / or improving mouse fertility outcome.

The invention relates to application of ergothioneine in preparation of a preparation for improving an ovarian reserve function. The invention creatively discovers that the ergothioneine has the function of improving the ovarian reserve function, and the obvious clinical value of the ergothioneine for people with the serum AMH level of 1.0-3.0 ng / mL in the key'window phase 'is defined for the first time. The ergothioneine not only can improve the serum AMH level and the sinus follicle count (AFC), but also can significantly reduce the abnormally increased FSH and LH levels. Meanwhile, aiming at bone loss caused by ovarian reserve function decline, the ergothioneine shows an excellent bone quality protection effect, the bone density can be improved, and the thickness and number of bone trabecula can be increased. In addition, the ergothioneine can improve climacteric symptoms, effectively maintain the nutritional state of target organs such as uterus, delay atrophy and regulate menstrual cycle disorder.

The present invention relates to the field of biomarker technology, specifically to a blood biomarker combination for the prediction and auxiliary diagnosis of diminished ovarian reserve (DOR), a corresponding detection kit, and its applications. This invention, for the first time, screens for changes in the levels of nicotinamide mononucleotide (NMN) and its metabolite combination in serum or plasma, which can serve as a detection indicator for predicting DOR. Based on this biomarker combination, the present invention further provides an in vitro detection kit comprising relevant standards, internal standard solutions, and extracts, as well as a data analysis method combined with a random forest model, capable of accurately distinguishing individuals with normal ovarian reserve from those with diminished DOR. The method of the present invention is non-invasive, simple, and highly sensitive, making it suitable for the early identification and stratified screening of DOR in clinical practice.

This invention discloses a compound moxa stick for warming yang and unblocking obstruction, its preparation method, and its application in improving reproductive system function. It belongs to the field of external preparations of traditional Chinese medicine. Addressing the problems of limited improvement effects of pure moxa sticks, lack of systematic design in compound moxa stick formulations, unclear synergistic effects between components, large fluctuations in conditioning effects, and difficulty in balancing conditioning effects and safety, this invention uses specific weight proportions of Artemisia argyi, Cyperus rotundus, Alpinia galanga, Cinnamomum cassia, Zingiber officinale, Illicium verum, Cinnamomum cassia twig, Spatholobus suberectus, Caesalpinia sappan, Smilax glabra, Euonymus fortunei, Citrus aurantium, Amomum villosum, Citrus reticulata peel, and Atractylodes lancea to prepare a compound moxa stick. The components synergistically enhance each other, and this product is used to prepare a moxibustion intervention product for improving the reproductive function of mammals. It can stably improve female ovarian reserve function and male asthenospermia, simultaneously regulate reproductive-related hormone levels, repair pathological damage to reproductive organs, and improve the quality of reproductive cells.

The invention belongs to the technical field of traditional Chinese medicine preparation, and discloses a traditional Chinese medicine composition for assisting pregnancy and implantation in a test tube and a preparation method thereof, and the traditional Chinese medicine composition is prepared from the following medicinal materials: teasel root, parasitic loranthus, semen cuscutae, radix paeoniae alba, liquorice, divaricate saposhnikovia root, roasted rhizoma atractylodis macrocephalae, pericarpium citri reticulatae, ramie root, scutellaria baicalensis, Chinese yam, fructus amomi, coptis chinensis, dogwood, radix rehmanniae preparata, folium mori, bamboo shavings and loofah sponge charcoal. The traditional Chinese medicine composition can regulate spleen and kidney deficiency states, improve ovarian blood flow, improve serum sex hormone level, increase endometrial thickness and vascular endothelial growth factor expression, contribute to endometrial growth, improve endometrial receptivity, assist implantation and development of reproductive embryos and improve pregnancy success rate of patients, and has good application prospects. The traditional Chinese medicine composition has more obvious effect on patients with ovarian reserve function decline, and is worthy of clinical popularization and application.

The invention relates to the technical field of traditional Chinese medicines, in particular to application of a prepared rehmannia root extract in preparation of a medicine for treating ovarian injury. The inventor finds a single traditional Chinese medicine for treating ovarian injury based on a traditional Chinese medicine compound core medicinal material data mining model. The prepared rehmannia root is taken as a representative core medicinal material screened and output by a model, efficacy verification is carried out in a cyclophosphamide induced ovarian injury mouse model, and the result shows that the prepared rehmannia root can improve E2 and AMH levels, reduce FSH and LH levels, improve orbital cycle disorder and reduce oxidative stress level, so that the prepared rehmannia root can improve the ovarian reserve function of a mouse, and can be used for treating ovarian injury. And a certain improvement effect is achieved on ovarian injury. The invention provides a quantifiable traditional Chinese medicine compound medicinal material screening thought, realizes a closed loop of a method from data mining to efficacy verification, and provides a theoretical basis and an experimental basis for developing novel traditional Chinese medicines for treating ovarian injury.

This invention discloses the application of N-acetyl-L-tryptophan, including the following applications: a. application in the preparation of drugs or health products that improve ovarian reserve function; b. application in the preparation of drugs or health products that improve or treat oocyte maturation disorders. This invention also discloses a drug comprising: N-acetyl-L-tryptophan or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, or an excipient; said drug can improve or treat oocyte maturation disorders and improve ovarian reserve function. This invention also discloses a health product comprising: N-acetyl-L-tryptophan or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, or an excipient; said health product can improve or treat oocyte maturation disorders and improve ovarian reserve function. This invention is the first to discover that N-acetyl-L-tryptophan has the efficacy of improving or treating oocyte maturation disorders and improving ovarian reserve function.

The invention belongs to the technical field of biology, and particularly relates to application of phosphatidyl glycerol. According to the invention, phosphatidyl glycerol PG (20: 422: 6) is taken as a biomarker, follicular fluid metabolites are analyzed, and high-sensitivity, high-specificity and high-accuracy diagnosis of the hypoovarian reserve function (DOR) is realized.

The invention relates to an ovarian reserve, endocrine age and aging trend integrated evaluation system for female fertility planning, and the system comprises a data collection module which is used for obtaining the data of the age and the anti-mullerian hormone (AMH) level of a subject; the module for calculating the low ovarian response function is used for calculating the data acquired in the data acquisition module so as to calculate the low ovarian response probability (p) of the subject and further converting the low ovarian response probability into a standardized ovarian reserve score; a module for calculating the endocrine age of the subject, wherein the endocrine age of the subject is calculated by using the low ovarian response probability of the subject; and the module is used for predicting the age of the change of the ovarian reserve of the subject, and the endocrine age of the subject is used for predicting the age limit or age of the new change of the ovarian reserve of the subject. By using the system and the method of the invention, the female at the childbearing age can be timely helped to know the optimal childbearing opportunity.

The application belongs to the technical field of biology and specifically relates to application of phosphatidylethanolamine. The application takes phosphatidylethanolamine PE (16:0_22:5) as a biomarker, realizes high sensitivity, high specificity and high accuracy in diagnosis of decreased ovarian reserve (DOR) by analyzing metabolites of follicular fluid.

One aspect of the invention provides a method of ovarian protection by administering to a female subject a composition comprising Mullerian inhibiting substance (MIS). Ovarian protection can be an induced arrest of folliculogenesis to preserve fertility. In some embodiments, ovarian protection is oncoprotection, the protection of the ovarian function during a cytotoxic treatment, e.g., chemotherapy. Another aspect of the invention relates to a method of treating PCOS, the method comprising administering to a female subject a composition comprising recombinant MIS protein.